熊去氧胆酸联合氢化可的松对胆汁淤积型肝炎患者肝功能及生活质量的影响  

Effects of Ursodeoxycholic Acid Combined with Hydrocortisone on Liver Function and Quality of Life in Patients with Cholestatic Hepatitis

作　　者：谢慧杰 XIE Hui-jie(GI Medicine Department,Anyang Third People's Hospital,Anyang Henan 455000,China)

机构地区：[1]安阳市第三人民医院消化内科,河南安阳455000

出　　处：《药品评价》2020年第10期27-28,36,共3页Drug Evaluation

摘　　要：目的:探究熊去氧胆酸联合氢化可的松对胆汁淤积型肝炎患者肝功能及生活质量的影响。方法:选取我院2016年12月-2019年12月胆汁淤积型肝炎患者68例,根据治疗方案不同分组,各34例。对照组给予综合保肝、对症治疗,观察组于对照组基础上加用熊去氧胆酸、氢化可的松。对比两组疗效、平均起效时间、住院时间及治疗前后肝功能指标[谷丙转氨酶(ALT)、总胆红素(TBil)、碱性磷酸酶(ALP)、谷氨酰转肽酶(GGT)]、血清肿瘤坏死因子α(TNF-α)与细胞间黏附分子-1(ICAM-1)水平、慢性肝病问卷(CLDQ)评分。结果:观察组总有效率高于对照组(P<0.05);观察组平均起效时间、住院时间短于对照组(P<0.05);治疗后观察组ALT、TBil、ALP、GGT低于对照组(P<0.05);治疗后观察组血清TNF-α、ICAM-1水平低于对照组(P<0.05);治疗后观察组CLDQ评分高于对照组(P<0.05)。结论:熊去氧胆酸联合氢化可的松治疗胆汁淤积型肝炎患者,可降低血清TNF-α、ICAM-1水平,加快病情恢复,改善肝功能,提高生活质量,疗效显著。Objective:To investigate the effect of ursodeoxycholic acid combined with hydrocortisone on liver function and quality of life in patients with cholestatic hepatitis.Methods:A total of 68 patients with cholestatic hepatitis from December 2016 to December 2019 in our hospital were selected and grouped according to different treatment plans,34 in each group.The control group was given comprehensive liver protection and symptomatic treatment,and the observation group added ursodeoxycholic acid and hydrocortisone on the basis of the control group.Comparing the efficacy,average onset time,length of hospitalization and liver function indexes[alanine aminotransferase(ALT),total bilirubin(TBil),alkaline phosphatase(ALP),glutamyl transpeptidase(GGT)],serum tumor necrosis factor alpha(TNF-α)and intercellular adhesion molecule-1(ICAM-1)levels,and chronic liver disease questionnaire(CLDQ)scores before and after treatment between two groups.Re sults:The total effective rate of the observation group was higher than that of the control group(P<0.05);the average onset time and hospitalization time of the observation group were shorter than that of the control group(P<0.05);after treatment,ALT,TBil,ALP and GGT of observation group were lower than those of control group(P<0.05);after treatment,the serum TNF-αand ICAM-1 levels in the observation group were lower than those in the control group(P<0.05);the CLDQ score of the observation group after treatment was higher than that of the control group(P<0.05).Conclusion:Ursodeoxycholic acid combined with hydrocortisone in the treatment of patients with cholestasis hepatitis can reduce serum TNF-αand ICAM-1 levels,accelerate the recovery of the disease,improve liver function,improve the quality of life,and have a significant effect.

关 键 词：熊去氧胆酸 氢化可的松 胆汁淤积型肝炎 肝功能 生活质量 

分 类 号：R575.1[医药卫生—消化系统]